BRAF and hepatocellular carcinoma: In addition, PI3K-pathway activation occurs concomitantly with RAS/BRAF mutations in CRC.41 Furthermore, understanding the PI3K pathway will lead to more effective treatments and biomarker identification in CRC patients.42, 43 In our previous report, altered expression of FUT6 markedly modulated the activity of the PI3K/Akt pathway in human hepatocellular carcinoma cell lines.44 However, the report did not discuss the PI3K/Akt pathway as a downstream target of FUT5.